Email this article 
Post a Comment 
A case report of long term bevacizumab treatment in multiresistant ovarian cancer
Abstract
Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic treatment. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. Bevacizumab is generally introduced in combination with chemotherapy; however this case report will describe the use of single-agent bevacizumab for more than five years (102 cycles) in a patient with relapse of advanced ovarian cancer.
Keywords
Full Text:
PDFReferences
Available from http://eu-cancer.iarc.fr/EUCAN/CancerOne.aspx?Cancer=27&Gender=2
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent overaian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5): 229–39.
Monk BJ, Pujade-Lauraine E, Burger RA. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. Ann Oncol. 2013;24(suppl.10):x53-8.
Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000582/WC500112811.pdf
Burger RA, Brady MF, Bookman MA et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365:2473-83.
Perren TJ, Swart AM, Pfisterer J et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 2011;365:2484-96.
Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemotherapy For Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol. 32:1302-8.
Aghajanian C, Blank SV, Goff BA et al. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2012;30:2039-45.
Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-6.
Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71.
DOI: http://dx.doi.org/10.14319/ijcto.42.14
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013